NPI 1588066021: Open Payments
NPI 1588066021. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$363 in 24 payments from 11 companies in 2025. Trend: 2023 $341 · 2024 $336 · 2025 $363
Food & beverage: $363
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $54 |
| Abbott Laboratories | 3 | $49 |
| SANOFI-AVENTIS U.S. LLC | 2 | $38 |
| Exact Sciences Corporation | 2 | $38 |
| Novo Nordisk Inc | 2 | $37 |
| Avvisto Therapeutics, LLC | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Astellas Pharma US Inc | 2 | $28 |
| IBSA Pharma Inc. | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: JARDIANCE, FREESTYLE LIBRE, TZIELD, Rybelsus, CYCLOSET, Veozah, Tirosint, The Cologuard Plus Collection Kit.
